12:00 AM
Mar 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MVA-BN- HER2 vaccine: Phase I/II data

Data from a Phase I/II trial showed that MVA-BN-HER2 vaccine generated an immune response against epidermal growth factor (EGF) receptor 2 (HER2, ErbB2, neu) in about 70% of...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >